By Canadian Press

Medicago reports promising early Phase 1 test results of possible COVID-19 vaccine

Nov 10, 2020 | 7:53 AM

QUEBEC — Medicago says it has received promising early test results for its plant-derived vaccine for COVID-19.

The Quebec City-based company says interim results of a Phase 1 clinical trial found that 100 per cent of subjects developed a promising antibody response after two doses of its COVID-19 vaccine candidate.

Medicago says the side effects were generally mild to moderate and short in duration.

The Phase 1 clinical trial was a randomized, partially blinded study of 180 healthy people.

Based on the Phase 1 data, Medicago plans to proceed with a Phase 2/3 clinical trial for its COVID-19 vaccine candidate, subject to regulatory approval.

Meaningful Mementos

Remembering Someone You've Lost at Christmas

Dec 03, 2024

Seasonal Sorrow

How Do You Get Through The Holidays When You're Grieving?

Nov 01, 2024

Upcoming Events at Oliver's

Grief & Loss and Estate Planning Seminars

Oct 02, 2024

The federal government has signed deal with Medicago to secure the rights to buy 76 million doses of its vaccine. Medicago will also receive $173 million in funding from Ottawa for its vaccine research and development and for the  construction of its Quebec City manufacturing facility.

This report by The Canadian Press was first published Nov. 10, 2020.

The Canadian Press

Note to readers: This is a corrected story. An earlier version incorrectly described the federal government funding.